RS62465B1 - Imatinib za upotrebu u lečenju moždanog udara - Google Patents
Imatinib za upotrebu u lečenju moždanog udaraInfo
- Publication number
- RS62465B1 RS62465B1 RS20211286A RSP20211286A RS62465B1 RS 62465 B1 RS62465 B1 RS 62465B1 RS 20211286 A RS20211286 A RS 20211286A RS P20211286 A RSP20211286 A RS P20211286A RS 62465 B1 RS62465 B1 RS 62465B1
- Authority
- RS
- Serbia
- Prior art keywords
- imatinib
- day
- dose
- patient
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650260A SE539450C2 (en) | 2016-02-29 | 2016-02-29 | Imatinib for use in the treatment of stroke |
| EP17760399.0A EP3423060B1 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
| PCT/SE2017/050183 WO2017151043A1 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS62465B1 true RS62465B1 (sr) | 2021-11-30 |
Family
ID=59744327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20211286A RS62465B1 (sr) | 2016-02-29 | 2017-02-27 | Imatinib za upotrebu u lečenju moždanog udara |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10953010B2 (enExample) |
| EP (1) | EP3423060B1 (enExample) |
| JP (1) | JP6914957B2 (enExample) |
| CN (2) | CN119523986A (enExample) |
| AU (1) | AU2017227515B2 (enExample) |
| DK (1) | DK3423060T3 (enExample) |
| ES (1) | ES2895432T3 (enExample) |
| HR (1) | HRP20211621T1 (enExample) |
| HU (1) | HUE056798T2 (enExample) |
| LT (1) | LT3423060T (enExample) |
| PL (1) | PL3423060T3 (enExample) |
| PT (1) | PT3423060T (enExample) |
| RS (1) | RS62465B1 (enExample) |
| RU (1) | RU2739382C1 (enExample) |
| SE (1) | SE539450C2 (enExample) |
| SI (1) | SI3423060T1 (enExample) |
| WO (1) | WO2017151043A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10617756B2 (en) * | 2017-01-05 | 2020-04-14 | Shimojani, LLC | Drug regimen for treatment of cerebral ischemia |
| CN114306342B (zh) * | 2020-09-30 | 2024-06-28 | 江苏先声药业有限公司 | 一种注射用伊马替尼盐的药物组合物及其制备方法 |
| CN118524852A (zh) * | 2021-11-09 | 2024-08-20 | 真和制药有限公司 | 治疗或抑制心血管疾病的方法 |
| EP4311539A1 (en) | 2022-07-29 | 2024-01-31 | Artorange Ltd. | Imatinib formulation for parenteral administration |
| US20250000934A1 (en) | 2023-06-28 | 2025-01-02 | Pharmazz, Inc. | Lyophilized sovateltide-based injectable formulation and method for preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY148074A (en) * | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
| EP2021028A2 (en) | 2006-04-17 | 2009-02-11 | Ludwig Institute For Cancer Research | Methods and compositions for modulation of blood-neural barrier |
| US7977348B2 (en) * | 2006-04-27 | 2011-07-12 | Sicor Inc. | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α |
| EP2076507A2 (en) * | 2006-10-26 | 2009-07-08 | Sicor, Inc. | Imatinib base, and imatinib mesylate and processes for preparation thereof |
| US20100136094A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| TR201911199T4 (tr) * | 2009-03-27 | 2019-08-21 | Moleac Pte Ltd | Hücre büyümesini arttırmak için tedavi. |
-
2016
- 2016-02-29 SE SE1650260A patent/SE539450C2/en not_active IP Right Cessation
-
2017
- 2017-02-27 CN CN202411509669.3A patent/CN119523986A/zh active Pending
- 2017-02-27 US US16/080,529 patent/US10953010B2/en active Active
- 2017-02-27 LT LTEPPCT/SE2017/050183T patent/LT3423060T/lt unknown
- 2017-02-27 SI SI201730931T patent/SI3423060T1/sl unknown
- 2017-02-27 HU HUE17760399A patent/HUE056798T2/hu unknown
- 2017-02-27 DK DK17760399.0T patent/DK3423060T3/da active
- 2017-02-27 HR HRP20211621TT patent/HRP20211621T1/hr unknown
- 2017-02-27 JP JP2018545843A patent/JP6914957B2/ja active Active
- 2017-02-27 RU RU2019122730A patent/RU2739382C1/ru active
- 2017-02-27 WO PCT/SE2017/050183 patent/WO2017151043A1/en not_active Ceased
- 2017-02-27 PL PL17760399T patent/PL3423060T3/pl unknown
- 2017-02-27 ES ES17760399T patent/ES2895432T3/es active Active
- 2017-02-27 CN CN201780013732.6A patent/CN108697711A/zh active Pending
- 2017-02-27 RS RS20211286A patent/RS62465B1/sr unknown
- 2017-02-27 PT PT177603990T patent/PT3423060T/pt unknown
- 2017-02-27 EP EP17760399.0A patent/EP3423060B1/en active Active
- 2017-02-27 AU AU2017227515A patent/AU2017227515B2/en active Active
-
2021
- 2021-02-26 US US17/186,303 patent/US20210236488A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT3423060T (pt) | 2021-10-20 |
| AU2017227515B2 (en) | 2022-03-24 |
| ES2895432T3 (es) | 2022-02-21 |
| JP2019507165A (ja) | 2019-03-14 |
| SE539450C2 (en) | 2017-09-26 |
| LT3423060T (lt) | 2021-11-10 |
| CN108697711A (zh) | 2018-10-23 |
| RU2739382C1 (ru) | 2020-12-23 |
| JP6914957B2 (ja) | 2021-08-04 |
| CN119523986A (zh) | 2025-02-28 |
| EP3423060B1 (en) | 2021-07-21 |
| US10953010B2 (en) | 2021-03-23 |
| DK3423060T3 (da) | 2021-10-25 |
| SE1650260A1 (en) | 2017-08-30 |
| WO2017151043A1 (en) | 2017-09-08 |
| AU2017227515A1 (en) | 2018-08-30 |
| EP3423060A1 (en) | 2019-01-09 |
| SI3423060T1 (sl) | 2021-11-30 |
| US20210236488A1 (en) | 2021-08-05 |
| HUE056798T2 (hu) | 2022-03-28 |
| EP3423060A4 (en) | 2020-01-01 |
| US20190030030A1 (en) | 2019-01-31 |
| PL3423060T3 (pl) | 2022-01-10 |
| HRP20211621T1 (hr) | 2022-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Diringer et al. | Aneurysmal subarachnoid hemorrhage: strategies for preventing vasospasm in the intensive care unit | |
| US20210236488A1 (en) | Imatinib for use in the treatment of stroke | |
| JP6208235B2 (ja) | 多発性硬化症治療のためのビオチンの使用 | |
| JP2023053274A (ja) | Ｃｎｓ浮腫に関連する損傷または状態を処置する方法 | |
| Lutsep et al. | Neuroprotection in acute ischaemic stroke: current status and future potential | |
| JP2010518181A (ja) | 心血管疾患の処置のためのラノラジンの使用 | |
| Suzuki et al. | Cilostazol improves outcome after subarachnoid hemorrhage: a preliminary report | |
| US20090076105A1 (en) | Preventive or therapeutic agent for cerebral ischemic injury or cerebral ischemia reperfusion in stroke | |
| Ahmed et al. | Epidemiology, pathophysiology, and current treatment strategies in stroke | |
| Moavero et al. | Everolimus alleviates obstructive hydrocephalus due to subependymal giant cell astrocytomas | |
| CA2558169A1 (en) | Method of treatment of myocardial infarction | |
| WO2023123468A1 (zh) | 心脑血管药物及其应用 | |
| US20080200481A1 (en) | Method of treatment of myocardial infarction | |
| EP3747430A1 (en) | Application of 5-hydroxytryptamine receptor 1a in preparing drug for portal hypertension | |
| AU2003293037A1 (en) | Method of treatment of myocardial infarction | |
| KR20190134825A (ko) | 수축력 저하 수반성 배뇨근 과활동 개선제 | |
| Pastromas | Newer Anticoagulants for Atrial Fibrillation: the Role of Dabigatran, Rivaroxaban, Apixaban and Edoxaban/RELY, ROCKET-AF, ARISTOTLE, & ENGAGE AF TIMI 48 Studies/Safety Issues | |
| Appelboom¹ et al. | for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage | |
| RU2578472C1 (ru) | Способ лечения злокачественной опухоли головного мозга | |
| Katayoun Vahedi | Surgery for acute ischemic stroke | |
| KR20250114057A (ko) | 맥관 기형용 의약 조성물 및 맥관 기형의 치료 방법 | |
| Klein | ACP Journal Club. Review: new oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF. | |
| ARJUNDAS et al. | Management of acute ischaemic stroke | |
| Pastromas | ANTITHROMBOTIC THERAPY IN CARDIOLOGY | |
| JPH08291066A (ja) | 一過性脳虚血発作抑制剤 |